Moderna Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Moderna, Inc. MRNA will release its fourth-quarter financial results, before the opening bell, on Friday, Feb. 14, 2025.

Analysts expect the Cambridge, Massachusetts-based company to report a quarterly loss at $2.68 per share, versus earnings of 55 cents per share in the year-ago period. Moderna projects quarterly revenue of $942.84 million, compared to $2.81 billion a year earlier, according to data from Benzinga Pro.

The company has topped consensus estimates on the top and bottom lines for the last four consecutive quarters.

Moderna shares gained 4.5% to close at $31.92 on Thursday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

• B of A Securities analyst Tim Anderson maintained an Underperform rating and cut the price target from $41 to $34 on Feb. 11, 2025. This analyst has an accuracy rate of 62%.
• Evercore ISI Group analyst Cory Kaimov maintained an In-Line rating and cut the price target from $60 to $50 on Jan. 27, 2025. This analyst has an accuracy rate of 69%.
• Argus Research analyst John Eade downgraded the stock from Buy to Hold on Dec. 18, 2024. This analyst has an accuracy rate of 74%.
• JP Morgan analyst Jessica Fye maintained an Underweight rating and cut the price target from $59 to $45 on Nov. 26, 2024. This analyst has an accuracy rate of 62%.

Considering buying MRNA stock? Here’s what analysts think:

Read This Next:

• Top 3 Consumer Stocks You May Want To Dump In February